NIKKEI 225
27,433.40 +50.84 (+0.19%) HANG SENG
22,020.47 -668.43 (-2.95%) CRUDE OIL
79.14 -0.54 (-0.68%) GOLD FUTURES
1,940.30 -5.30 (-0.27%) DOW
33,978.08 +28.68 (+0.08%) BTC-GBP
19,106.29 +265.68 (+1.41%)
Bayer Aktiengesellschaft (BAYN.DE)
| Previous close | 56.04 |
| Open | 56.18 |
| Bid | 0.00 x 28400 |
| Ask | 0.00 x 2100 |
| Day's range | 56.01 - 56.62 |
| 52-week range | 46.70 - 67.99 |
| Volume | |
| Avg. volume | 2,540,774 |
| Market cap | 55.291B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | 11.77 |
| EPS (TTM) | 4.78 |
| Earnings date | 28 Feb 2023 |
| Forward dividend & yield | 2.00 (3.57%) |
| Ex-dividend date | 02 May 2022 |
| 1y target est | 74.70 |
- Reuters
Bayer investor calls for swift replacement of CEO: newspaper
Bayer investor Deka has called for CEO Werner Baumann to be replaced ahead of his scheduled departure, adding to mounting pressure on the German drugmaker. "Bayer needs a new strategic positioning, which cannot be credibly accomplished under Werner Baumann," Ingo Speich, head of sustainability and corporate governance at Deka, told the Frankfurter Allgemeine Sonntagszeitung (FAS) newspaper in remarks published on Saturday. The mutual funds firm is among Bayer's 20 largest shareholders.
- Motley Fool
The Top Healthcare Stocks to Buy With $100
Bayer Aktiengesellschaft (OTC: BAYR.Y) and AstraZeneca (NASDAQ: AZN) are elite healthcare companies with shares that trade for less than $100 and make excellent long-term investments because of their revenue and earnings growth, promising pipelines, and above-average dividends. Bayer was down 11.2% in 2022 and currently trades for about $15 a share while AstraZeneca was up 16.4% in 2022 and currently trades for around $70 a share. Bayer is a huge German life science conglomerate.
- Reuters
Bayer investor criticizes Bayer chair for lack of initiative - WirtschaftsWoche
FRANKFURT (Reuters) -The Bayer investor Union Investment criticized Bayer's chair for a lack of engagement, such as exploring a spin-off of the company's consumer health division, according to an interview in WirtschaftsWoche. Bayer is facing demands from activist investor Bluebell Capital Partners to break up, with a sale of the company's consumer health unit and, at a later stage, for a separation of Bayer's pharmaceuticals and agriculture businesses. Bayer Chair Norbert Winkeljohann "does seek dialogue with investors, but he should have initiated more," Markus Manns, portfolio manager at Union Investment, told WirtschaftsWoche.
